Sylentis Aims to Begin Phase I Study of Glaucoma Drug in September

The disclosure comes about a month after the company announced that it had received clearance from Spanish regulators to begin the trial, in line with its previously disclosed guidance.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.